The relationships between mild cognitive impairment and phenotype in Parkinson's disease

Parkinson's Disease

Volumn 1, Issue , 2015, Pages

  Szeto, Jennifer Y Y ^a   O'Callaghan, Claire ^a,b   Shine, James M ^a   Walton, Courtney C ^a   Mowszowski, Loren ^a   Naismith, Sharon L ^a   Halliday, Glenda M ^b   Lewis, Simon J G ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BEHAVIOR DISORDER; CLUSTER ANALYSIS; DAYTIME SOMNOLENCE; DISEASE COURSE; FEMALE; GAIT; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; PHENOTYPE; POST HOC ANALYSIS; PREVALENCE; REM SLEEP; SLEEP DISORDER;

EID: 84978955006     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1038/npjparkd.2015.15     Document Type: Article

References (50)

1. Lewis SJG, Barker RA. Understanding the dopaminergic deficits in Parkinson's disease: Insights into disease heterogeneity. J Clin Neurosci 2009; 16: 620-625.
2. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 2014; 29: 634-650.
3. Kroener S, Chandler LJ, Phillips PE, Seamans JK. Dopamine modulates persistent synaptic activity and enhances the signal-to-noise ratio in the prefrontal cortex. PLoS One 2009; 4: e6507.
4. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787-1798.
5. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349-356.
6. Lewis SJG, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005; 76: 343-348.
7. Reijnders J, Ehrt U, Lousberg R, Aarsland D, Leentjens AFG. The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 379-382.
8. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinicopathological study of subtypes in Parkinson's disease. Brain 2009; 132: 2947-2957.
9. Gasparoli E, Delibori D, Polesello G, Santelli L, Ermani M, Battistin L et al. Clinical predictors in Parkinson's disease. Neurol Sci 2002; 23: s77-s78.
10. Poletti M, Frosini D, Pagni C, Baldacci F, Nicoletti V, Tognoni G et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2012; 83: 601-606.
11. Post B, Speelman JD, De Haan RJ. Clinical heterogeneity in newly diagnosed Parkinson's disease. J Neurol 2008; 255: 716-722.
12. Katzen HL, Levin BE, Llabre ML. Age of disease onset influences cognition in Parkinson's disease. J Int Neuropsychol Soc 1998; 4: 285-290.
13. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979; 29: 1253-1253.
14. Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol 2014; 27: 434-441.
15. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007; 22: 2314-2324.
16. Szeto JYY, Mowszowski L, Gilat M, Walton CC, Naismith SL, Lewis SJ. Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord 2015; 21: 31-35.
17. Johns MW. Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the Epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 2000; 9: 5-11.
18. Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003; 26: 1049-1054.
19. Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire - A new diagnostic instrument. Mov Disord 2007; 22: 2386-2393.
20. Tremblay C, Achim AM, Macoir J, Monetta L. The heterogeneity of cognitive symptoms in Parkinson's disease: a meta-analysis. J Neurol Neurosurg Psychiatry 2013; 84: 1265-1272.
21. Spiegel J, Hellwig D, Samnick S, Jost W, Möllers M-O, Fassbender K et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J Neural Transm 2007; 114: 331-335.
22. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958-2969.
23. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013; 84: 1258-1264.
24. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221: 564-573.
25. Delaville C, De Deurwaerdère P, Benazzouz A. Noradrenaline and Parkinson's disease. Front Syst Neurosci 2011; 5: 31.
26. Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain 2014; 137: 2493-2508.
27. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and Parkinsonian dementia. J Neurol 2006; 253: 242-247.
28. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease: a follow-up study of untreated patients. Brain 1992; 115: 1701-1725.
29. Bédard M-A, Pillon B, Dubois B, Duchesne N, Masson H, Agid Y. Acute and longterm administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome. Brain Cogn 1999; 40: 289-313.
30. Hall JM, Shine JM, Walton CC, Gilat M, Kamsma YPT, Naismith SL et al. Early phenotypic differences between Parkinson's disease patients with and without freezing of gait. Parkinsonism Relat Disord 2014; 20: 604-607.
31. Lewis SJ, Shine JM. The next step: a common neural mechanism for freezing of gait. Neuroscientist 2014, 1-11.
32. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391-403.
33. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002; 18: 258-264.
34. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D et al. Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2009; 35: 881-892.
35. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001; 16: 135-139.
36. Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time. J Neurol Neurosurg Psychiatry 2008; 79: 387-391.
37. Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs 2011; 25: 203-212.
38. Grinberg LT, Rueb U, Alho AT, Heinsen H. Brainstem pathology and non-motor symptoms in PD. J Neurol Sci 2010; 289: 81-88.
39. Sinforiani E, Zangaglia R, Manni R, Cristina S, Marchioni E, Nappi G et al. REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson's disease. Mov Disord 2006; 21: 462-466.
40. Pacchetti C, Manni R, Zangaglia R, Mancini F, Marchioni E, Tassorelli C et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005; 20: 1439-1448.
41. Walton CC, Shine JM, Mowszowski L, Gilat M, Hall JM, O'Callaghan C et al. Impaired cognitive control in Parkinson's disease patients with freezing of gait in response to cognitive load. J Neural Transm 2015; 122: 653-660.
42. Hirano S, Shinotoh H, Eidelberg D. Functional brain imaging of cognitive dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 2012; 83: 963-969.
43. Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013; 80: 85-91.
44. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C et al. Lewy-and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011; 134: 1493-1505.
45. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J et al. Tau and α-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007; 62: 145-153.
46. Foltynie T, Goldberg TE, Lewis SG, Blackwell AD, Kolachana BS, Weinberger DR et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 2004; 19: 885-891.
47. McCann H, McGeachie AB, Silberstein P, Lewis SJ, Halliday GM. Restricted disease propagation in multiple system atrophy with prolonged survival. Neuropathol Appl Neurobiol 2014; 41: 681-685.
48. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry 2011; 82: 1033-1037.
49. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M et al. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol 2014; 71: 62-67.
50. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 492-496.